tbResList Print — MO Moringa oleifera

Filters: qv=209, qv2=%, rfv=%

Product

MO Moringa oleifera
Description: <b>The leaves, seeds, and pods of the Moringa oleifera plant</b> contain a variety of bioactive compounds, including flavonoids, phenolic acids, and saponins, which have been shown to have anti-inflammatory, antioxidant, and anti-proliferative effects.<br>
Moringa oleifera extracts on various types of cancer: Breast, Lung, Colon, Prostate<br>
<pre>
Moringa (Moringa oleifera) is not a single compound.
Cancer-related data are primarily from:
-Leaf extracts (polyphenols, quercetin, kaempferol)
-Isothiocyanates (e.g., moringin)
-Glucosinolates
-Alkaloids and other secondary metabolites
Mechanistically it behaves as a mixed redox-modulating phytochemical extract, not a strong direct cytotoxin.
</pre>
<br>

<p><b>Moringa oleifera</b> — a nutrient-rich medicinal and food plant of the Moringaceae family whose leaves, seeds, pods, and other tissues contain complex mixtures of glucosinolates, isothiocyanates, flavonoids, phenolic acids, alkaloids, sterols, and other phytochemicals. It is a botanical/nutraceutical rather than a single molecular agent; common abbreviations include MO and MOL for Moringa oleifera and Moringa oleifera leaf. The leaves are the most commonly consumed and studied oral preparation. Important bioactives include glucomoringin and its myrosinase-derived isothiocyanate moringin, together with quercetin- and kaempferol-related flavonoids. Anticancer activity is predominantly preclinical and varies substantially with plant part, extraction method, phytochemical composition, and concentration.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of mitochondrial and caspase-dependent apoptosis, including Bax ↑, Bcl-2 ↓, mitochondrial membrane potential ↓, cytochrome-c release, and caspase activation.</li>
<li>Redox modulation, including ROS ↑ in several cancer models but antioxidant/ROS-lowering effects in many normal-cell and tissue models; direction is strongly preparation- and context-dependent.</li>
<li>Suppression of pro-survival inflammatory signaling, particularly NF-κB and associated inflammatory mediators.</li>
<li>Cell-cycle arrest through p21, p53, cyclin/CDK, and related regulatory mechanisms, commonly involving G1 or G2/M arrest depending on model.</li>
<li>Modulation of PI3K/AKT, MEK/ERK, JNK/p38 MAPK, and other growth/stress signaling pathways.</li>
<li>Suppression of invasion, migration, angiogenesis, and metastasis-associated signaling in selected preclinical models.</li>
<li>Chemosensitization, including enhanced cisplatin cytotoxicity in pancreatic cancer cells; evidence remains preclinical.</li>
<li>NRF2/ARE activation and induction of antioxidant/detoxification enzymes, primarily relevant to cytoprotection and chemoprevention; its effect in established tumors is context-dependent rather than uniformly anticancer.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> Oral exposure cannot be represented by a single PK profile because Moringa is a heterogeneous botanical preparation. Glucomoringin requires hydrolysis, including by myrosinase, to generate moringin and related isothiocyanate activity. Processing and extraction conditions substantially alter isothiocyanate delivery. Human pharmacokinetic data for the major putative anticancer constituents remain limited, and standardized preparations are required for meaningful dose comparisons.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Many cancer-cell experiments use concentrated crude extracts in the tens to hundreds of µg/mL range and sometimes approximately 0.75 mg/mL or higher. Equivalent circulating concentrations of whole Moringa extract after ordinary oral leaf consumption have not been demonstrated and are unlikely to be directly reproduced systemically. Purified isothiocyanates and locally generated gastrointestinal metabolites should therefore be distinguished from crude-extract concentration experiments when evaluating clinical plausibility.</p>

<p><b>Clinical evidence status:</b> Cancer — preclinical. Antiproliferative and antitumor effects have been demonstrated in numerous cell models and a smaller number of animal studies, but controlled clinical evidence establishing Moringa as a cancer treatment or cancer adjunct is lacking. Human studies exist mainly in metabolic, nutritional, inflammatory, and maternal-health settings rather than oncology. Moringa is consumed as food and marketed as a botanical supplement, not as an approved anticancer drug. Leaf preparations have generally been well tolerated in short human studies, but long-term high-dose safety, standardized oncology dosing, drug interactions, and the safety of non-leaf preparations are insufficiently characterized.</p>



<br>
<h3>Moringa oleifera – Bioactive Ingredients and Concentrations</h3>
<table border="1" cellpadding="4" cellspacing="0">
<thead>
<tr>
<th>Rank</th>
<th>Active Ingredient</th>
<th>Class</th>
<th>Concentration mg/g DW</th>
<th>Amount per 5 g</th>
<th>Principal Activity</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Glucomoringin</td>
<td>Glucosinolate</td>
<td>33.9–59.4</td>
<td>169.5–297 mg</td>
<td>Precursor of moringin; potential anti-inflammatory and anticancer activity</td>
<td>Selected reported leaf measurements. Highly dependent on cultivar, maturity, and preparation. Not a standardized concentration for commercial powders.</td>
</tr>
<tr>
<td>2</td>
<td>Moringin (glucomoringin isothiocyanate); <a href="https://nestronics.ca/dbx/tbResList.php?qv=476">isothiocyanates</a></td>
<td>Isothiocyanate</td>
<td>Variable; not established</td>
<td>Not reliably quantified</td>
<td>NF-κB ↓; NRF2 ↑; anti-inflammatory and experimental anticancer effects</td>
<td>Generated from glucomoringin by myrosinase. Processing determines conversion. Link is to the general isothiocyanates product, not a moringin-specific entry.</td>
</tr>
<tr>
<td>3</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=140">Quercetin</a> and derivatives</td>
<td>Flavonoids</td>
<td>0.207–7.57</td>
<td>1.04–37.85 mg</td>
<td>Anti-inflammatory; redox modulation; experimental antiproliferative activity</td>
<td>Contains free and conjugated forms depending on analytical method. Glycosides may be included in some measurements.</td>
</tr>
<tr>
<td>4</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=316">Kaempferol</a> and derivatives</td>
<td>Flavonoids</td>
<td>ND–4.59</td>
<td>ND–22.95 mg</td>
<td>Cell-cycle modulation; apoptosis; anti-inflammatory activity</td>
<td>Includes glucosides, malonyl glucosides, and other conjugated forms. Some analyses report nondetectable concentrations.</td>
</tr>
<tr>
<td>5</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=127">Myricetin</a></td>
<td>Flavonoid</td>
<td>5.804</td>
<td>29.02 mg</td>
<td>Antioxidant; anti-inflammatory; experimental anticancer activity</td>
<td>Single reported measurement; not an established typical concentration.</td>
</tr>
<tr>
<td>6</td>
<td>Epicatechin</td>
<td>Flavanol</td>
<td>5.68</td>
<td>28.4 mg</td>
<td>Antioxidant and anti-inflammatory signaling</td>
<td>Reported in freeze-dried leaves. No separate database product identified.</td>
</tr>
<tr>
<td>7</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=59">Chlorogenic acid</a></td>
<td>Phenolic acid</td>
<td>0.018–0.489</td>
<td>0.09–2.45 mg</td>
<td>Antioxidant; metabolic and inflammatory regulation</td>
<td>Concentrations depend on extraction and analytical methods.</td>
</tr>
<tr>
<td>8</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=51">Caffeic acid</a></td>
<td>Phenolic acid</td>
<td>0.409–0.536</td>
<td>2.05–2.68 mg</td>
<td>Antioxidant and anti-inflammatory effects</td>
<td>Some studies report nondetectable concentrations.</td>
</tr>
<tr>
<td>9</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=82">Gallic acid</a></td>
<td>Phenolic acid</td>
<td>ND–1.034</td>
<td>ND–5.17 mg</td>
<td>Antioxidant; experimental antiproliferative effects</td>
<td>Highly variable analytical recovery.</td>
</tr>
<tr>
<td>10</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=77">Ferulic acid</a></td>
<td>Phenolic acid</td>
<td>0.078–0.128</td>
<td>0.39–0.64 mg</td>
<td>Antioxidant; cytoprotective effects</td>
<td>Reported in dried leaf preparations.</td>
</tr>
<tr>
<td>11</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=349">Lutein</a></td>
<td>Carotenoid</td>
<td>1.02</td>
<td>5.1 mg</td>
<td>Antioxidant; retinal and neuronal protection</td>
<td>Reported in freeze-dried leaves.</td>
</tr>
<tr>
<td>12</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=194">Beta-carotene</a></td>
<td>Carotenoid</td>
<td>0.163–0.66</td>
<td>0.82–3.3 mg</td>
<td>Provitamin A; antioxidant activity</td>
<td>Concentration varies with drying and storage.</td>
</tr>
<tr>
<td>13</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=307">Vitamin E</a> (tocopherols)</td>
<td>Vitamin</td>
<td>0.7445–1.22</td>
<td>3.72–6.1 mg</td>
<td>Lipid-phase antioxidant activity</td>
<td>Different tocopherol forms and analytical methods may be represented.</td>
</tr>
<tr>
<td>14</td>
<td>Isorhamnetin</td>
<td>Methylated flavonoid</td>
<td>0.118–0.72</td>
<td>0.59–3.6 mg</td>
<td>Anti-inflammatory; experimental antiproliferative activity</td>
<td>No separate product identified. Methylated quercetin derivative.</td>
</tr>
<tr>
<td>15</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=143">Rutin</a> (quercetin-3-O-rutinoside)</td>
<td>Flavonoid glycoside</td>
<td>0.390</td>
<td>1.95 mg</td>
<td>Antioxidant; anti-inflammatory; vascular protection</td>
<td>Direct published measurement in dried leaves. Rutin is a quercetin glycoside and must not be double-counted if total quercetin includes conjugates.</td>
</tr>
<tr>
<td>16</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=74">Ellagic acid</a></td>
<td>Polyphenolic acid</td>
<td>ND–0.189</td>
<td>ND–0.945 mg</td>
<td>Antioxidant; experimental anticancer activity</td>
<td>Low or nondetectable in some samples; limited systemic bioavailability of free ellagic acid.</td>
</tr>
<tr>
<td>17</td>
<td>o-Coumaric acid</td>
<td>Phenolic acid</td>
<td>6.457</td>
<td>32.285 mg</td>
<td>Antioxidant and anti-inflammatory activity</td>
<td>Single reported freeze-dried leaf measurement. Not interchangeable with p-coumaric acid.</td>
</tr>
<tr>
<td>18</td>
<td><a href="https://nestronics.ca/dbx/tbResList.php?qv=453">p-Coumaric acid</a></td>
<td>Phenolic acid</td>
<td>ND</td>
<td>Not quantified</td>
<td>Antioxidant; anti-inflammatory effects</td>
<td>Not detected in the referenced freeze-dried leaf analysis. Separate isomer from o-coumaric acid.</td>
</tr>
</tbody>
</table>
<p><b>Notes:</b> ND = not detected; DW = dry weight. Values are literature measurements from different cultivars, drying procedures, extraction protocols, and analytical methods. They are not necessarily representative of retail leaf powder. The 5 g amounts are theoretical conversions, not measured oral exposure or bioavailability. Glycosides, aglycones, and precursor-derived products must not be double-counted.</p>
<p><b>Interpretation:</b> ND means not detected. The amount per 5 g is a mathematical conversion of reported analytical values, not an expected dose from a commercial product. Glucomoringin and moringin must not be added together as independent constituents because moringin is formed from its precursor. Flavonoid measurements can include different free and conjugated forms.</p>





<h3>Cancer-Related Mechanisms</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Mitochondrial apoptosis</td>
<td>Bax ↑; Bcl-2 ↓; ΔΨm ↓; cytochrome-c ↑; caspase-9 and caspase-3/7 ↑</td>
<td>↔ or apoptosis ↓ (context-dependent)</td>
<td>R, G</td>
<td>Apoptotic cell death</td>
<td>Among the most reproducible anticancer phenotypes across several leaf extracts and isolated fractions; evidence remains predominantly cellular and animal.</td>
</tr>
<tr>
<td>2</td>
<td>ROS and oxidative stress</td>
<td>ROS ↑ (context-dependent); oxidative stress ↑</td>
<td>ROS ↓; SOD ↑; catalase ↑; GPx ↑; GSH preservation ↑</td>
<td>P, R</td>
<td>Selective redox stress</td>
<td>Biphasic response is important. Pro-oxidant activity occurs in several cancer models, whereas antioxidant activity predominates in many non-cancer models.</td>
</tr>
<tr>
<td>3</td>
<td>NF-κB inflammatory and survival signaling</td>
<td>NF-κB ↓; p65 ↓; inflammatory survival signaling ↓</td>
<td>NF-κB ↓ (inflammatory models)</td>
<td>R, G</td>
<td>Survival and inflammatory signaling suppression</td>
<td>Repeatedly reported for leaf-derived preparations and relevant to both tumor survival and inflammatory signaling.</td>
</tr>
<tr>
<td>4</td>
<td>Cell-cycle regulation</td>
<td>p21 ↑; p53 ↑ (model-dependent); G1 or G2/M arrest ↑</td>
<td>↔</td>
<td>G</td>
<td>Cytostasis</td>
<td>Phase of arrest varies by tumor type and preparation. Some leukemia models show p21-dependent effects without significant p53 modulation.</td>
</tr>
<tr>
<td>5</td>
<td>PI3K and AKT survival signaling</td>
<td>AKT signaling ↓ or altered (model-dependent)</td>
<td>↔ or AKT ↑ during neuroprotection</td>
<td>R, G</td>
<td>Growth and survival suppression</td>
<td>Direction is strongly tissue-dependent; activation of AKT can be protective in stressed neurons, so this is not a universal inhibitory action of Moringa.</td>
</tr>
<tr>
<td>6</td>
<td>MEK ERK and stress MAPK signaling</td>
<td>MEK/ERK ↓ in some models; JNK/p38 modulation (model-dependent)</td>
<td>↔</td>
<td>R, G</td>
<td>Growth suppression and apoptotic signaling</td>
<td>Dalton lymphoma studies support MEK/ERK inactivation, while other preparations produce different MAPK signatures.</td>
</tr>
<tr>
<td>7</td>
<td>Invasion angiogenesis and metastatic signaling</td>
<td>Migration ↓; MMP-associated signaling ↓; VEGF-associated signaling ↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Anti-invasive and anti-angiogenic activity</td>
<td>Supported by selected experimental models but less consistent than apoptosis, redox, and NF-κB effects.</td>
</tr>
<tr>
<td>8</td>
<td>Chemosensitization</td>
<td>Cisplatin cytotoxicity ↑</td>
<td>Not established</td>
<td>G</td>
<td>Chemotherapy sensitization</td>
<td>Synergy has been demonstrated in pancreatic cancer cells with aqueous leaf extract; clinical validation is absent.</td>
</tr>
<tr>
<td>9</td>
<td>NRF2 ARE antioxidant response</td>
<td>NRF2 modulation (context-dependent)</td>
<td>NRF2 ↑; antioxidant and detoxification enzymes ↑</td>
<td>R, G</td>
<td>Cytoprotection and chemoprevention</td>
<td>More convincing as a normal-tissue protective or prevention mechanism than as a direct mechanism against established cancer; persistent NRF2 activation could theoretically protect some tumors.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>Crude-extract activity commonly requires high concentrations</td>
<td>Oral leaf use generally produces dietary or nutraceutical exposure</td>
<td>G</td>
<td>Exposure and standardization limitation</td>
<td>Plant part, cultivar, drying, extraction, myrosinase activity, glucomoringin conversion, and constituent bioavailability vary substantially. Human anticancer exposure-response relationships have not been established.</td>
</tr>
</table>
<p>P: 0–30 min &nbsp;&nbsp;&nbsp; R: 30 min–3 hr &nbsp;&nbsp;&nbsp; G: &gt;3 hr</p>







<br><br>
<hr>
<br><br>


<p><b>Alzheimer’s disease relevance:</b> Moringa oleifera has meaningful but still preclinical AD relevance. Animal and cellular studies report reductions in amyloidogenic processing and Aβ burden, inhibition of Aβ aggregation, improvement of synaptic proteins and cognitive performance, antioxidant and anti-inflammatory activity, and acetylcholinesterase inhibition. Reported targets include BACE1 ↓, AEP ↓, Aβ ↓, IDE ↑, NEP ↑, LRP1 ↑, PSD95 ↑, synapsin-related signaling ↑, oxidative stress ↓, and AChE ↓. These findings justify an AD section in the database, but no adequate human trial currently establishes efficacy for prevention or treatment of Alzheimer’s disease.</p>


<h3>Alzheimer’s Disease Mechanisms</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Amyloid production and clearance</td>
<td>BACE1 ↓; AEP ↓; Aβ ↓; IDE ↑; NEP ↑; LRP1 ↑</td>
<td>G</td>
<td>Reduced amyloid burden</td>
<td>Strong preclinical evidence in APP/PS1 and related experimental models.</td>
</tr>
<tr>
<td>2</td>
<td>Aβ aggregation</td>
<td>Aβ aggregation ↓</td>
<td>R, G</td>
<td>Reduced amyloid assembly</td>
<td>Recent biophysical and cellular work shows Moringa leaf polyphenol-rich aqueous extracts can interfere with Aβ1-42 aggregation.</td>
</tr>
<tr>
<td>3</td>
<td>Oxidative stress and antioxidant defenses</td>
<td>ROS ↓; SOD ↑; catalase ↑; GPx ↑</td>
<td>P, R, G</td>
<td>Neuroprotection</td>
<td>One of the most consistently reported neuroprotective actions.</td>
</tr>
<tr>
<td>4</td>
<td>Synaptic plasticity</td>
<td>PSD95 ↑; synapsin-related signaling ↑; BDNF ↑ (model-dependent)</td>
<td>G</td>
<td>Synaptic preservation</td>
<td>Associated with improved memory and learning phenotypes in preclinical models.</td>
</tr>
<tr>
<td>5</td>
<td>Cholinergic signaling</td>
<td>AChE ↓; BChE ↓ (compound-dependent); ACh availability ↑</td>
<td>R, G</td>
<td>Cholinergic support</td>
<td>Supported predominantly by enzyme, cellular, and animal studies rather than clinical AD trials.</td>
</tr>
<tr>
<td>6</td>
<td>Neuroinflammation</td>
<td>NF-κB ↓; inflammatory cytokines ↓</td>
<td>R, G</td>
<td>Anti-neuroinflammatory activity</td>
<td>Likely interacts with antioxidant and amyloid-related mechanisms.</td>
</tr>
<tr>
<td>7</td>
<td>Neuronal survival and mitochondrial function</td>
<td>AKT CREB signaling ↑; mitochondrial dysfunction ↓; apoptosis ↓</td>
<td>R, G</td>
<td>Neuronal survival</td>
<td>Direction contrasts with the AKT suppression sometimes sought in cancer and illustrates the strong tissue dependence of Moringa signaling.</td>
</tr>
<tr>
<td>8</td>
<td>Clinical Translation Constraint</td>
<td>Human AD efficacy not established</td>
<td>G</td>
<td>Translation limitation</td>
<td>Extract standardization, CNS exposure, active constituent PK, effective human dose, and long-term safety require clinical investigation.</td>
</tr>
</table>
<p>P: 0–30 min &nbsp;&nbsp;&nbsp; R: 30 min–3 hr &nbsp;&nbsp;&nbsp; G: &gt;3 hr</p>



Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress(tgid=1) ⓘ

GPx↑, 1,   ROS↑, 3,   ROS↓, 1,  

Cell Death(tgid=5) ⓘ

AIF↑, 1,   Apoptosis↑, 5,   BAX↑, 3,   Bcl-2↓, 2,   Bcl-2↑, 1,   Casp↑, 1,   Casp3↑, 3,   Casp7↑, 1,   Casp9↑, 1,   Cyt‑c↑, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

EGFR↓, 1,   ERK↓, 1,   MAP2K1/MEK1↓, 1,   MEK↓, 1,   STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 2,   P53↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCP↓, 3,  

Migration(tgid=13) ⓘ

pol-TregCell↓, 1,   TumCMig↓, 1,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 2,   CD8+↑, 2,   COX2/PTGS2↓, 1,   Imm↑, 1,   NF-kB↓, 3,   NK cell↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   eff↑, 1,   selectivity↑, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 1,  
Total Targets: 42

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 13,   ARE↑, 2,   Bil↓, 1,   Catalase↑, 6,   GPx↑, 2,   GSH↑, 1,   GSR↑, 1,   GSTs↑, 2,   HDL↑, 1,   lipid-P↓, 3,   MDA↓, 5,   NQO1↑, 1,   NRF2↑, 2,   ROS↓, 10,   mt-ROS↓, 1,   SOD↑, 9,   TAC↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 2,   ATP↑, 1,   Glycolysis↑, 1,   GSK‐3β↓, 1,   HK2↑, 1,   LDL↓, 1,  

Cell Death(tgid=5) ⓘ

BAX↓, 1,   Bcl-2↓, 1,   Casp3↓, 1,   iNOS↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑Akt↑, 2,   Akt↑, 1,   p‑CREB↑, 1,   mTOR↑, 1,   PI3K↑, 1,   STEP↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3B↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↓, 1,   cal2↓, 1,   LRP1↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   GLUT4↑, 1,   MMP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL6↓, 2,   Imm↑, 1,   Inflam↓, 7,   PGE2↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

Ach↑, 2,   AChE↓, 7,   BChE↓, 1,   BDNF↑, 2,   PSD95↑, 1,  

Protein Aggregation(tgid=19) ⓘ

AEP↓, 1,   APP↓, 1,   Aβ↓, 2,   Aβ42↓, 2,   BACE/β-secretase↓, 3,   IDE↑, 1,   NEP↑, 1,   p‑tau↓, 3,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ACE/ACE1↓, 1,   PPARγ↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioEnh↑, 1,   Dose↝, 1,   eff↑, 4,   eff↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   ALP↓, 2,   AST↓, 2,   Bil↓, 1,   creat↓, 1,   IL6↓, 2,   TC↓, 1,   TG/TAG↓, 1,   VLDL↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 2,   AntiTum↑, 1,   cardioP↑, 1,   chemoPv↑, 1,   cognitive↑, 5,   hepatoP↑, 4,   Learn↑, 1,   memory↑, 7,   memory?, 1,   Mood↑, 2,   motorD↑, 1,   neuroP↑, 11,   radioP↑, 1,   RenoP↑, 2,   Sleep↑, 1,   toxicity↓, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   Bacteria↓, 1,   GutMicro↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 6,  
Total Targets: 96

Research papers

Year Title Authors PMID Link Flag
2022Cytotoxic and Genotoxic Evaluation of Biosynthesized Silver Nanoparticles Using Moringa oleifera on MCF-7 and HUVEC Cell LinesHatice AlkanPMC9143030https://pmc.ncbi.nlm.nih.gov/articles/PMC9143030/0
2023Natural angiotensin converting enzyme inhibitors: A safeguard against hypertension, respiratory distress syndrome, and chronic kidney diseasesAya Khaled37675925https://pubmed.ncbi.nlm.nih.gov/37675925/0
2026Therapeutic Potential of Moringa oleifera in Alzheimer’s Disease: A Review of Neuroprotective MechanismsHui YuPMC13291660https://pmc.ncbi.nlm.nih.gov/articles/PMC13291660/0
2026Moringa oleifera Lamk. as a Promising Adjunct Therapeutic Candidate: A Narrative Review of Human Studies and Published Case ReportsErlia Anggrainy SianiparPMC12912182https://pubmed.ncbi.nlm.nih.gov/41710586/0
2026Anticancer Potential of Moringa Oleifera in Lung Cancer: A Mini Review of In vitro and In vivo EvidenceLea El Masri42136470https://pubmed.ncbi.nlm.nih.gov/42136470/0
2025Harnessing Moringa oleifera for Immune Modulation in Cancer: Molecular Mechanisms and Therapeutic PotentialMounir TilaouiPMC12785612https://pmc.ncbi.nlm.nih.gov/articles/PMC12785612/0
2025Synergistic Neuroprotection in Tauopathic Mice via Green-Synthesized Silver Nanoparticles Co-delivering Methylene Blue and Moringa oleiferaYasmin ElbermawyPMC12743692https://pmc.ncbi.nlm.nih.gov/articles/PMC12743692/0
2025Moringa oleifera Extracts as Strategic Phyto‐Therapy for Alzheimer's DiseaseRita CarrottaPMC11938381https://pmc.ncbi.nlm.nih.gov/articles/PMC11938381/0
2025Effect of Moringa oleifera on inflammatory diseases: an umbrella review of 26 systematic reviewsThiala Soares Josino da Silva ParentePMC12127422https://pmc.ncbi.nlm.nih.gov/articles/PMC12127422/0
2025Characterization of the Anticholinesterase and Antioxidant Properties of Phytochemicals from Moringa oleifera as a Potential Treatment for Alzheimer’s DiseaseAdel M AljadaanPMC12467246https://pmc.ncbi.nlm.nih.gov/articles/PMC12467246/0
2024Anticancer effect of Moringa oleifera in oral squamous cell carcinoma: a systematic reviewChandini RajkumarPMC11582275https://pmc.ncbi.nlm.nih.gov/articles/PMC11582275/0
2024Water Extracts of Moringa oleifera Leaves Alter Oxidative Stress-Induced Neurotoxicity in Human Neuroblastoma SH-SY5Y CellsAgian Jeffilano BarindaPMC11578659https://pmc.ncbi.nlm.nih.gov/articles/PMC11578659/0
2023Moringa oleifera L. leaf extract induces cell cycle arrest and mitochondrial apoptosis in Dalton's Lymphoma: An in vitro and in vivo studySandeep Kumar36306933https://pubmed.ncbi.nlm.nih.gov/36306933/0
2022The Oil Formulation Derived from Moringa Oleifera Seeds Ameliorates Behavioral Abnormalities in Water-immersion Restraint Stress Mouse ModelEmni PurwoningsihPMC9792812https://pmc.ncbi.nlm.nih.gov/articles/PMC9792812/0
2022Characterization, Large-Scale HSCCC Separation and Neuroprotective Effects of Polyphenols from Moringa oleifera LeavesQian GaoPMC8840448https://pmc.ncbi.nlm.nih.gov/articles/PMC8840448/0
2022Effects of Moringa oleifera on working memory: an experimental study with memory-impaired Wistar rats tested in radial arm mazeSadia AfrinPMC9528094https://pmc.ncbi.nlm.nih.gov/articles/PMC9528094/0
2022Moringa Oleifera Alleviates Aβ Burden and Improves Synaptic Plasticity and Cognitive Impairments in APP/PS1 MiceYacoubou Abdoul Razak MahamanPMC9609596https://pmc.ncbi.nlm.nih.gov/articles/PMC9609596/0
2021Moringa oleifera-supplemented diet protect against cortico-hippocampal neuronal degeneration in scopolamine-induced spatial memory deficit in mice: role of oxido-inflammatory and cholinergic neurotransmission pathwaySamuel Adetunji Onasanwo—https://link.springer.com/article/10.1007/s11011-021-00855-90
2021Phenolic Extraction of Moringa Oleifera Leaves Induces Caspase-Dependent and Caspase-Independent Apoptosis through the Generation of Reactive Oxygen Species and the Activation of Intrinsic Mitochondrial Pathway in Human Melanoma CellsBich Hang Do32530312https://pubmed.ncbi.nlm.nih.gov/32530312/0
2021Nutritional Value of Moringa oleifera Lam. Leaf Powder Extracts and Their Neuroprotective Effects via Antioxidative and Mitochondrial RegulationElena González-BurgosPMC8308447https://pmc.ncbi.nlm.nih.gov/articles/PMC8308447/0
2021Moringa oleifera: A Tree of Life as a Promising Medicinal Plant for Neurodegenerative DiseasesSaurav Ghimire34843254https://pubmed.ncbi.nlm.nih.gov/34843254/0
2018Moringa Oleifera Alleviates Homocysteine-Induced Alzheimer's Disease-Like Pathology and Cognitive ImpairmentsYacoubou Abdoul Razak MahamanPMC6004908https://pmc.ncbi.nlm.nih.gov/articles/PMC6004908/0
2017Bioactive Components in Moringa Oleifera Leaves Protect against Chronic DiseaseMarcela Vergara-JimenezPMC5745501https://pmc.ncbi.nlm.nih.gov/articles/PMC5745501/0
2015Review of the Safety and Efficacy of Moringa oleiferaSidney J StohsPMC6680322https://pmc.ncbi.nlm.nih.gov/articles/PMC6680322/0
2014Protective effects of Moringa oleifera Lam. leaves against arsenic-induced toxicity in miceAfzal SheikhPMC4025314https://pmc.ncbi.nlm.nih.gov/articles/PMC4025314/0
2013Cerebroprotective effect of Moringa oleifera against focal ischemic stroke induced by middle cerebral artery occlusionWoranan KirisattayakulPMC3866794https://pmc.ncbi.nlm.nih.gov/articles/PMC3866794/0
2013Moringa oleifera Mitigates Memory Impairment and Neurodegeneration in Animal Model of Age-Related DementiaChatchada SutalangkaPMC3884855https://pmc.ncbi.nlm.nih.gov/articles/PMC3884855/0
2011Bioenhancers from mother nature and their applicability in modern medicineGurpreet Kaur RandhawaPMC3657948https://pmc.ncbi.nlm.nih.gov/articles/PMC3657948/0